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the comparable estimates would be C$11.65/person (HC) and C$0.84/person (FC). 
ICER of HD vs IIV3 was C$190/QALY with HC approach and C$3,106/QALY with FC. 
In comparison, the difference of ICERs of IIV4 vs IIV3 was small - $16,232/QALY (HC) 
and C$19,028/QALY (FC). Exclusion of productivity costs of mortality had minimal 
impact with similar ICERs to FC method. CONCLUSIONS: The differences in ICERs of 
IIV4 vs IIV3 with HC method, FC method or no productivity costs of mortality were 
significantly narrower than those of HD vs IIV3. Relative vaccine efficacy against 
influenza-related deaths to IIV3 was a key driver of productivity costs; therefore, 
choice of methods could be crucial with massively different results. Those conclu-
sions were robust to alternative friction periods and elastic factors.
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OBJECTIVES: Colombia is an endemic country for malaria. Burden of disease and 
costs estimations are scarce. The aim of this analysis is to estimate the burden 
of disease and the diagnosis and care costs of malaria, from the surveillance 
data. METHODS: A malaria transmission model was built from an age-dependent 
Markov process, to simulate the morbidity and mortality of the malaria infection 
in the Colombian population from the national surveillance system and other 
literature. The model included a birth cohort followed up to their life expectancy. 
We estimated the number of malaria, malaria complicates and death cases in the 
cohort during the life span. From the official malaria diagnosis and treatment 
guidelines we captured the frequency of use for all cost items and calculated 
the cost per patient from the tariff manual and international prices. Cost esti-
mation was carried out from the third payer perspective. We estimated the dis-
ability adjusted life years (DALYs) and diagnosis and care costs for each malaria 
case and entire population during 2012 splitting by different Plasmodium specie. 
All costs were reported in 2012 American dollars (exchange rate of US$ 1768.23.
per COP). RESULTS: During 2012 we estimated 65.448 cases and 32 deaths due 
to malaria. The 71.7% of cases were due to P. vivax and 27.0% by P. falciparum. 
Complications were presented in 1% of all cases. All malaria cases sum a burden 
of disease of 1902 DALYs (mainly due to year of life lost-YLL, 1878). Total estimated 
cost was US$936.253, 5% of them due to complicated malaria. CONCLUSIONS: 
Burden and costs of disease due to malaria in Colombia are relevant in spite of 
availability of effective preventive measurements. Cost-effectiveness of different 
public health interventions should be evaluate for the decision making process 
and this model will be a valuable input for that task.
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OBJECTIVES: Data on costs of surgical site infections (SSIs) following ambulatory 
surgery are sparse, despite a shift towards outpatient procedures. We determined 
the impact of serious and non-serious SSIs on healthcare costs following common 
ambulatory surgical procedures throughout the cost distribution. METHODS: We 
conducted a retrospective cohort study of persons < 65 years coded for cholecys-
tectomy, breast-conserving surgery (BSC), anterior cruciate ligament reconstruction 
(ACL), or hernia repair from 12/31/2004–12/31/2010 using commercial insurer claims 
data. SSIs within 90 days after surgery were identified by ICD-9-CM diagnosis codes. 
Infections during inpatient hospitalization or resulting in surgical treatment were 
considered serious. Quantile regression controlling for underlying illness, operative 
variables, demographics, and surgical facility type was used to examine the impact 
of serious and non-serious SSIs on 180-day healthcare costs. RESULTS: The inci-
dence of serious/non-serious SSIs (# procedures) were 0.8%/0.2% after ACL (21,062), 
0.5%/0.3% after cholecystectomy (57,750), 0.6%/0.5% after hernia repair (60,681), and 
0.8%/0.8% after BCS (42,489). Serious SSIs were associated with significantly higher 
costs than non-serious SSIs for ACL, cholecystectomy, and hernia repair at all points 
examined in the cost distribution. For BCS, serious SSIs were associated with sig-
nificantly higher costs at the upper end (> = 80th percentile) of the cost distribution. 
The ratio of adjusted total costs for individuals with serious SSI vs. no SSI increased 
for both cholecystectomy and hernia repair as the total cost increased (3.2 for chol-
ecystectomy with serious SSI/no SSI at the 70th percentile of costs, up to 4.9 at the 
95thpercentile). CONCLUSIONS: SSIs, particularly serious infections resulting in 
hospitalization or surgical treatment, were associated with significantly increased 
healthcare costs after 4 common surgical procedures performed in inpatient and 
ambulatory settings. Quantile regression illustrated the impact of serious SSIs on 
healthcare costs across the distribution of costs, especially at the upper end of the 
cost distribution.
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OBJECTIVES: Antibiotic resistance (ABR) poses a threat to public health in the United 
States (US). The Centers for Disease Control and Prevention has identified three 
ABR urgent threats (defined as potential clinical and economic impact, transmis-
sibility, available treatment, barriers to prevention): Clostridium difficile (C. diff), 
carbapenem-resistent Enterobacteriaceae (CRE), and Neisseria gonorrhoeae (N. gon-
orrhoeae). Limited data exist which document ABR-related burden in the context 
of inpatient care. This study examines length of stay (LOS) and costs associated 
with ABR urgent threat-related hospitalizations in the US. METHODS: Using the 
2001-2012 Healthcare Cost and Utilization Project’s Nationwide Inpatient Sample 
databases, nationally-representative surveys of US hospitalizations, we identified 
hospitalizations with a diagnosis code indicating an urgent ABR threat. LOS and 
societal perspective. Replacing IIV3 with IIV4 would result a net societal budget 
impact of over C$3 million. The ICER of IIV4 vs IIV3 is C$20,733 per QALY gained 
from healthcare perspective and societally C$16,232 per QALY gained. At $50,000 
per QALY gained threshold, 100% and 93.8% of PSA simulations were cost-effective 
for HD and IIV4, respectively, from healthcare perspective, and 95.3% for IIV4 from 
societal perspective. HD becomes a dominant alternative when long-term care costs 
are considered. CONCLUSIONS: Both HD and IIV4 are expected to reduce influenza-
associated morbidity and mortality, and are cost-effective in the studied population 
comparing to IIV3; however, IIV4 is extended dominated by HD. Those conclusions 
were proven to be robust in sensitivity analyses.
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OBJECTIVES: Access to effective, low cost antiretrovirals (ARVs) is a public health 
imperative. This study compared ARV approvals and prices in Saudi Arabia (SA) 
and the United States (US) in 2014. METHODS: US Food and Drug Administration 
(FDA) ARV drug approvals data were collected from the FDA website. Likewise, 
ARV drug approvals and prices in SA were collected from the Saudi Food and Drug 
Administration (SFDA) website. ARV drug prices data were also collected from the 
World Health Organization (WHO) website. Descriptive analysis and paired t-test 
were performed. Statistical significance was set up at 0.05% RESULTS: In 2014, there 
were 27 ARVs and 9 fixed-dose combinations of ARVs approved by the FDA. The WHO 
listed 22 ARV single active ingredients and 16 combinations. Overall, 29.6% of the 
single active ingredients and 33.3% of the combinations approved by the FDA were 
marketed in SA. The FDA approved generic ARVs for 18.5% of the single active ingre-
dients and for 22.2% of the combinations. The WHO listed generic ARVs for 31.8% of 
the single active ingredients and 100% of the combination drugs. No generic ARV 
drugs were approved by the SFDA. Price data were available for 13 drugs. ARV drug 
prices in SA were in median 21.14 times higher than the ARV drug prices listed by the 
WHO (range 2.2 - 99.8 times) (p< 0.0001). CONCLUSIONS: Less than one third of the 
ARV drugs approved by the US FDA were marketed in SA in 2014. Prices in SA were 
significantly higher than prices listed by the WHO. Lack of SFDA approved generic 
ARVs may explain the price difference. Approvals of low cost generic ARVs remains 
a public health priority in SA to improve quality of life of HIV patients in the country.
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OBJECTIVES: To evaluate the cost of influenza vaccination, the sources of financing, 
and drug cost compared to the cost of vaccination in Ukraine. METHODS: We used 
the statistic data of the MoH of Ukraine, data about the rate of influenza vaccina-
tion. Comparative analysis of retrospective data on consumption of drugs and the 
cost of influenza vaccine. RESULTS: Vaccination against influenza and other acute 
respiratory infections (ARI) are not included in the list of obligatory vaccinations and 
not funded by the state, partially it funded from local budgets in Ukraine. During 
2009-2010 flu had pandemic status, but the number of vaccinated people was mini-
mal. It has been vaccinated 239104 people, among them the expense of businesses 
- 94546 (39.5%), local budgets - 106498 (44.5%) and patient funds - 38060 (15.9%). Only 
2.18% people over 60 years were vaccinated, but this category represents 15.9% of 
the total population. We conducted that average cost of flu vaccination was 101,0 
UAH (1 USD = 16,5 UAH). The average cost of ambulatory treatment per patient 
was 241,1 UAH, it was 2,4 times more than the vaccination cost Analysis of sales 
of drugs used for treatment of flu and ARI showed: NSAIDS were spent 118,8 mln. 
UAH., Expectorants - 275,3 mln., Antibiotics – 218,1 mln., but the cost of vaccines 
were 23,2 mln. UAH. The comparison showed that the cost of drugs for the treatment 
of influenza and ARI were at 26.4 times more than vaccines. CONCLUSIONS: We 
evaluated the high rate of incidence of influenza, low rate of influenza vaccination 
in 2009, a low percentage of vaccination of health-risk groups (for example, 60 +), the 
high cost on drugs to treat the flu and ARI. It confirmed the economic expediency 
of using influenza vaccine in Ukraine.
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OBJECTIVES: Although employment rate is lower in the elderly population, different 
methods valuing productivity loss can yield contrasting incremental cost-effective-
ness ratios (ICER). This research aims to compare the impact of human capital (HC) 
and friction cost (FC) methods on productivity costs and incremental cost-effective-
ness ratios (ICERs) of replacing IIV3 with either high dose (HD) or quadrivalent (IIV4) 
among adults aged 65 and over in Ontario. METHODS: Population-level influenza 
outcomes from either Ontario or Canada with provincial wage data set were used 
to calculate the productivity loss due to physician visits, ED visits, hospitalizations 
and premature deaths. Vaccines efficacies were extracted from clinical studies and 
published literatures. HC and FC utilized discounted life expectancy and 90-day 
friction period, respectively. Alternative friction periods and elasticity factors were 
analyzed. RESULTS: With IIV3 under the current Universal Influenza Immunization 
Program (UIIP), the productivity costs due to influenza-related premature mortality 
is C$11.92/person and C$0.86/person with HC and FC approach, respectively. Those 
per person for HD in place of IIV3 would be C$9.13 (HC) and C$0.65 (FC); for IIV4, 
